Drug discovery and mental illness

Dialogues in Clinical Neuroscience

Volumn 4, Issue 4, 2002, Pages 325-328

  Lebowitz, Barry D ^a   Harris, Herbert W ^b  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b Vela Pharmaceuticals   (United States)

Author keywords

Clinical trial; Drug development; Mechanism based paradigm; Mental illness

Indexed keywords

ANTICONVULSIVE AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BIOLOGICAL MARKER; CHLORPROMAZINE; DOPAMINE RECEPTOR BLOCKING AGENT; IMIPRAMINE; LITHIUM; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN UPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

BIPOLAR DISORDER; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MARKER; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; FINANCIAL MANAGEMENT; GENOMICS; HUMAN; MEDICAL DOCUMENTATION; MEDICAL LITERATURE; MENTAL DISEASE; METHODOLOGY; MONOTHERAPY; MULTICENTER STUDY; OUTCOMES RESEARCH; PATHOPHYSIOLOGY; PATIENT SELECTION; PROTEOMICS; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; STATISTICAL ANALYSIS; VALIDATION PROCESS;

EID: 0038670217     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (16)

1. Murray CJL, Lopez AD. The Global Burden of Disease. Cambridge, Mass: Harvard University Press; 1996.
2. World Health Organization (WHO). World Health Report. Mental Heath: New Understanding, New Hope. Geneva, Switzerland: WHO; 2002.
3. Freeman H (ed). A Century of Psychiatry. Volume 1. London, UK: Mosby-Wolfe Medical Communications; 1999.
4. Collins FS. Shattuck lecture: medical and societal consequences of the Human Genome Project. N Engl J Med. 1999;341:28-37.
5. McKusick VA. The anatomy of the human genome: a neo-Vesalian basis for medicine in the 21st century. JAMA. 2001;286:2289-2295.
6. Subramanian G, Adams MD, Venter JC, Broder S. Implications of the human genome for understanding human biology and medicine. JAMA. 2001;286:2296-2307.
7. Service RF. Proteomics. High-speed biologists search for gold in proteins. Science. 2001;294:2074-2077.
8. Paul S. CNS drug discovery in the 21st century. From genomics to combinatorial chemistry and back. Br J Psychiatry Suppl. 1999;37:23-25.
9. Peltonen L, McKusick VA. Genomics and medicine: dissecting human disease in the postgenomic era. Science. 2001;291:1224-1229.
10. Collins FS, Guttmacher AE. Genetics moves to the medical mainstream. JAMA. 2001;286:2322-2324.
11. DeGruttola VG, Clax P, De Mets DL, et al. Considerations in the evaluation of surrogate endpoints in clinical trials. Summary of a National Institutes of Health workshop. Contr Clin Trials. 2001;22:485-502.
12. Mathis CA, Backsai BJ, Kajdasz ST, et al. A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. Bioorg Med Chem Lett. 2002;12:295-298.
13. Shoghi-Jadid K, Small GW, Agdeppa ED, et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry. 2002;10:24-35.
14. Lebowitz BD. A public health approach to clinical therapeutics in psychiatry: directions for new research. Dialogues Clin Neurosci. 2000;2:309-314.
15. Yusef S, Collins R, Peto R. Why do we need some large simple randomized trials? Stat Med. 1984;3:409-420.
16. National Institute for Clinical Excellence (NICE). Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. Technology Appraisal Guidance-No. 43. London, UK: NICE; 2002.